Navigation Links
Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
Date:6/2/2008

Landmark Study Shows Increased Survival for Non-Small Cell Lung Cancer

WASHINGTON, June 2 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) hailed the release of promising data from the pivotal Phase III First Line in Lung Cancer with Erbitux(R) (FLEX) Study. The data, presented at the American Society of Clinical Oncology (ASCO), showed a significant increase in overall survival in the first line treatment of patients with non-small cell lung cancer (NSCLC).

"This is very exciting news," said Laurie Fenton Ambrose, LCA President & CEO. "The FLEX data shows significant improvements in overall survival for a broad base of patients with no new safety concerns. This is so important to the lung cancer community because it will provide patients and doctors with another treatment option to consider when managing their diagnosis."

The FLEX study, conducted by Merck KGaA, enrolled more than 1,100 patients with Stage IIIb or IV NSCLC who had not previously received chemotherapy. The study included patients of all ages, regardless of their performance status (general well-being) who were diagnosed with all types of NSCLC. Erbitux(R) is a monoclonal antibody designed to inhibit the function of the epidermal growth factor receptor (EGFR). The major side effect from the drug is a rash.

Lung cancer is the leading cancer killer of both men and women in the United States with more than 162,000 deaths expected to occur in 2008, accounting for almost 30% of all cancer deaths.

"This is an important development," said David H. Johnson, MD, Deputy Director, Vanderbilt Ingram Cancer Center. "All lung cancer is notoriously difficult to treat. These results will further our understanding of NSCLC and provide a new standard of care for the lung cancer community."

For more information on the data please visit http://www.asco.org .

Lung Cancer Alliance ( http://www.lungcanceralliance.org ) is the only national non-profit organization dedicated solely to patient support and advocacy for those living with or at risk for lung cancer. LCA is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

Media Contact:

Kay Cofrancesco

kay@lungcanceralliance.org

202-744-1541


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):